Biogen Inc (BIIB)

Interest coverage

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	1,543,300	1,838,900	3,346,900	3,931,900	3,926,300	4,144,500	3,083,300	1,838,600	1,862,200	1,411,700	2,040,700	3,999,100	5,215,400	6,550,000	7,354,400	7,090,100	7,233,900	6,937,900	6,998,100	6,390,200
Interest expense (ttm)	US$ in thousands	246,900	230,200	226,300	243,000	246,600	258,100	264,500	255,100	253,700	243,400	233,400	243,000	222,600	212,600	202,100	183,800	187,400	190,800	194,000	198,000
Interest coverage		6.25	7.99	14.79	16.18	15.92	16.06	11.66	7.21	7.34	5.80	8.74	16.46	23.43	30.81	36.39	38.58	38.60	36.36	36.07	32.27

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $1,543,300K ÷ $246,900K
= 6.25

The interest coverage ratio for Biogen Inc has been fluctuating over the past eight quarters. Starting from Q1 2022 at 10.49, the ratio has shown a steady increase until it reached its highest point in Q1 2023 at 36.77, indicating the company's improved capability to cover its interest expenses using its operating income. This significant improvement over the period signifies stronger financial health and better debt servicing ability for Biogen Inc. However, the lack of data for Q2 to Q4 2023 limits a more comprehensive analysis of the company's recent performance in managing its interest obligations.